BioLogics will help Athera
Biotechnologies with development and manufacturing of its cardiovascular product. The recombinant protein Annexin A5
is intended for the treatment of patients with acute coronary syndrome who are at risk for myocardial infarction.
“We have now secured cost-competitive and high-quality production for clinical and commercial use,” notes Carina Schmidt, CEO of Athera Biotechnologies.
Athera’s candidate reported works by preventing plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. It was produced using Richter-Helm's E. coli-based expression system.
This agreement could include future large-volume commercial production of the molecule for Athera. Richter-Helm will initiate strain and process development of the new process, reaching a 1000 L production scale.